Cardiff Oncology Advances Onvansertib with FDA Alignment and ASCO Data Presentation
Event summary
- Cardiff Oncology completed an End-of-Phase 2 meeting with the FDA, aligning on the 30 mg dose of onvansertib and FOLFIRI/bev chemotherapy regimen for the planned Phase 3 trial in first-line RAS-mutated mCRC.
- The company will present updated Phase 2 CRDF-004 trial data at the ASCO Annual Meeting on May 29–June 2, 2026.
- Cardiff appointed Mani Mohindru as President and CEO, Josh Muntner as CFO, and Ajay Aggarwal as COO to strengthen leadership.
- As of March 31, 2026, Cardiff had $46.1 million in cash and cash equivalents, with a cash runway into Q1 2027.
The big picture
Cardiff Oncology's progress with onvansertib reflects the growing focus on targeted therapies for RAS-mutated cancers, a segment with high unmet medical need. The FDA's alignment on the Phase 3 trial design is a critical step, positioning the company to compete in the evolving colorectal cancer treatment landscape. The strategic leadership appointments underscore Cardiff's commitment to scaling its clinical and operational capabilities.
What we're watching
- Regulatory Strategy
- How the FDA's alignment on the Phase 3 trial design will impact the timeline and success of onvansertib's registration.
- Clinical Data
- Whether the updated Phase 2 data presented at ASCO will further validate onvansertib's potential in first-line RAS-mutated mCRC.
- Leadership Execution
- The pace at which the new executive team can drive clinical and regulatory milestones for onvansertib.
Related topics